10405-02-4 | Trospium Chloride

Packsize	Purity	Availability	Price	Discounted Price
25mg	98%	in stock	$22.00	$15.00
100mg	98%	in stock	$25.00	$18.00
1g	98%	in stock	$62.00	$44.00
5g	98%	in stock	$199.00	$139.00

Description

• Catalog Number: AD45919
• Chemical Name: Trospium Chloride
• CAS Number: 10405-02-4
• Molecular Formula: C25H30ClNO3
• Molecular Weight: 427.9636
• MDL Number: MFCD00865254
• SMILES: O=C(C(c1ccccc1)(c1ccccc1)O)OC1C[C@H]2CC[C@H](C1)[N+]12CCCC1.[Cl-]

Computed Properties

• Complexity: 553
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 2
• Heavy Atom Count: 30
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 5

Upstream Synthesis Route

Trospium chloride, a quaternary ammonium compound, is commonly used in chemical synthesis as a key building block in the creation of various pharmaceutical compounds. Its application in synthesis primarily involves its role as a highly selective muscarinic receptor antagonist. By incorporating Trospium chloride into synthetic routes, chemists can efficiently manipulate biological systems by modulating cholinergic neurotransmission. This versatile compound serves as a critical tool in the development of medications that target muscarinic receptors, making it essential in the pharmaceutical industry. Additionally, Trospium chloride's chemical properties enable precise control over its reactivity, making it a valuable component in the synthesis of a wide range of pharmacologically active molecules.

Literature

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics.

  Molecular pharmaceutics 20150105

• Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review.

  Annals of internal medicine 20120619

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.

  Journal of medicinal chemistry 20111013

• Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.

  Neurourology and urodynamics 20110901

• Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials.

  Neurourology and urodynamics 20110401

• Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome.

  BJU international 20110201

• Oxybutynin and trospium are substrates of the human organic cation transporters.

  Naunyn-Schmiedeberg's archives of pharmacology 20110201

• Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials.

  Drugs & aging 20110201

• Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder.

  Urology 20110101

• New once-daily formulation for trospium in overactive bladder.

  International journal of clinical practice 20101001

• New strategies for medical management of overactive bladder in children.

  Current opinion in urology 20100701

• Determination of the quaternary ammonium compound trospium in human plasma by LC-MS/MS: application to a pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100415

• Effects of combined use of trospium chloride and melatonin on in vitro contractility of rat urinary bladder.

  Urology 20100401

• Editorial comment.

  Urology 20100401

• Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults.

  Journal of clinical pharmacology 20100201

• Extended-release trospium chloride improves quality of life in overactive bladder.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100101

• Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence.

  BMC urology 20100101

• [Sexual dysfunction in women with overactive bladder and their correction with m-cholinolytic spasmex].

  Urologiia (Moscow, Russia : 1999) 20100101

• Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome.

  International urogynecology journal and pelvic floor dysfunction 20091201

• Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials.

  International journal of clinical practice 20091201

• Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.

  Clinical therapeutics 20091101

• Trospium and cognition in patients with late onset Alzheimer disease.

  The journal of nutrition, health & aging 20091001

• The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride.

  Drug metabolism and disposition: the biological fate of chemicals 20090701

• Trospium chloride treatment of overactive bladder.

  The Annals of pharmacotherapy 20090201

• [Spasmex in the treatment of overactive bladder. Russian experience].

  Urologiia (Moscow, Russia : 1999) 20090101

• The effects of reformulation: improved therapeutic index.

  Current urology reports 20081101

• Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects.

  European urology 20080501

• Overactive bladder disease: the urge for better therapies.

  Journal of managed care pharmacy : JMCP 20080501

• Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study.

  Urology 20080301

• Role of trospium chloride in brachytherapy-related detrusor overactivity.

  Urology 20080301

• [Comparative characteristics of M-cholinolytics in combined treatment of mixed urinary incontinence in women].

  Urologiia (Moscow, Russia : 1999) 20080101

• New drugs and dosage forms.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070915

• Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride.

  International urogynecology journal and pelvic floor dysfunction 20070901

• Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.

  The Journal of urology 20070901

• Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential.

  Geriatrics 20070501

• [M-cholinolytic spasmex and its role in preoperative preparation of patients with urine incontinence].

  Urologiia (Moscow, Russia : 1999) 20070101

• [Trospium chloride (spasmex) in the treatment of lower urinary tract symptoms in patients with neurogenic hyperactive urinary bladder caused by vertebrogenic lesions].

  Urologiia (Moscow, Russia : 1999) 20070101

• Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients?

  International journal of clinical pharmacology and therapeutics 20061201

• Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder.

  The Urologic clinics of North America 20061101

• Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?

  Naunyn-Schmiedeberg's archives of pharmacology 20061101

• Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin.

  Journal of clinical pharmacology 20060701

• Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.

  The American journal of medicine 20060301

• Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage.

  Neurourology and urodynamics 20060101

• [Tuberculosis of the urinary bladder: diagnosis and treatment].

  Urologiia (Moscow, Russia : 1999) 20060101

• Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder.

  Expert opinion on pharmacotherapy 20050701

• Overactive bladder.

  Cleveland Clinic journal of medicine 20050701

• The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder.

  The Journal of urology 20050501

• Trospium chloride for the treatment of overactive bladder with urge incontinence.

  Clinical therapeutics 20050501

• Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years.

  BJU international 20050201

• Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.

  Urology 20050201

• Clinical pharmacokinetics of trospium chloride.

  Clinical pharmacokinetics 20050101

• Contemporary and emerging drug treatments for urinary incontinence in children.

  Paediatric drugs 20050101

• [Neurological aspect of the hyperactive urinary bladder syndrome].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20050101

• [Trospium chloride in the treatment of idiopathic and neurogenic detrusor overactivity].

  Urologiia (Moscow, Russia : 1999) 20050101

• Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine.

  Current urology reports 20041001

• Elevating our therapeutic expectations in overactive bladder.

  Journal of the American Academy of Nurse Practitioners 20041001

• Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial.

  The Journal of urology 20040601

• [The combined treatment of interstitial cystitis in women with spasmex].

  Urologiia (Moscow, Russia : 1999) 20040101

• [Combined treatment of voiding disorders in women with m-cholinolytic and alpha 1-adrenoblocker].

  Urologiia (Moscow, Russia : 1999) 20040101

• Trospium chloride in the management of overactive bladder.

  Drugs 20040101

• Trospium chloride: a quaternary amine with unique pharmacologic properties.

  Current urology reports 20031201

• Update on overactive bladder: pharmacologic approaches on the horizon.

  Current urology reports 20031001

• Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability.

  World journal of urology 20030501

• [Urinary incontinence--treatment].

  Deutsche medizinische Wochenschrift (1946) 20030404

• [Spasmex treatment of patients with hyperactive urinary bladder].

  Urologiia (Moscow, Russia : 1999) 20030101

• Trospium chloride--an effective drug in the treatment of overactive bladder and detrusor hyperreflexia.

  World journal of urology 20011101

• Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.

  Journal of clinical pharmacology 20010601